The American Journal of Pathology
Volume 178, Issue 5 , Pages 1986-1998, May 2011

Tissue Microarray Cytometry Reveals Positive Impact of Homeodomain Interacting Protein Kinase 2 in Colon Cancer Survival Irrespective of p53 Function

  • Isabelle Soubeyran

      Affiliations

    • INSERM U916, Institut Bergonié, Université Victor Segalen Bordeaux 2, Bordeaux, France
  • ,
  • Isabelle Mahouche

      Affiliations

    • INSERM U916, Institut Bergonié, Université Victor Segalen Bordeaux 2, Bordeaux, France
  • ,
  • Aude Grigoletto

      Affiliations

    • INSERM U916, Institut Bergonié, Université Victor Segalen Bordeaux 2, Bordeaux, France
  • ,
  • Thierry Leste-Lasserre

      Affiliations

    • INSERM U862, Institut François Magendie, Université Victor Segalen Bordeaux 2, Bordeaux, France
  • ,
  • Guillaume Drutel

      Affiliations

    • INSERM U862, Institut François Magendie, Université Victor Segalen Bordeaux 2, Bordeaux, France
  • ,
  • Christophe Rey

      Affiliations

    • INSERM U916, Institut Bergonié, Université Victor Segalen Bordeaux 2, Bordeaux, France
  • ,
  • Stephane Pedeboscq

      Affiliations

    • INSERM U916, Institut Bergonié, Université Victor Segalen Bordeaux 2, Bordeaux, France
  • ,
  • France Blanchard

      Affiliations

    • INSERM U614, Faculté de Médecine, Institut de Recherche Biomédicale, Université de Rouen, Rouen, France
  • ,
  • Veronique Brouste

      Affiliations

    • INSERM U916, Institut Bergonié, Université Victor Segalen Bordeaux 2, Bordeaux, France
  • ,
  • Jean-Christophe Sabourin

      Affiliations

    • INSERM U614, Faculté de Médecine, Institut de Recherche Biomédicale, Université de Rouen, Rouen, France
  • ,
  • Yves Bécouarn

      Affiliations

    • INSERM U916, Institut Bergonié, Université Victor Segalen Bordeaux 2, Bordeaux, France
  • ,
  • Josy Reiffers

      Affiliations

    • INSERM U916, Institut Bergonié, Université Victor Segalen Bordeaux 2, Bordeaux, France
  • ,
  • François Ichas

      Affiliations

    • INSERM U916, Institut Bergonié, Université Victor Segalen Bordeaux 2, Bordeaux, France
    • FluoFarma, Pessac, France
  • ,
  • Francesca De Giorgi

      Affiliations

    • INSERM U916, Institut Bergonié, Université Victor Segalen Bordeaux 2, Bordeaux, France
    • FluoFarma, Pessac, France
    • Corresponding Author InformationAddress reprint requests to Francesca De Giorgi, Ph.D., INSERM U916, Institut Bergonié, Université Victor Segalen Bordeaux 2, 229 Cours de l'Argonne, 33076 Bordeaux Cedex, France

Accepted 25 January 2011.

The human p53 gene is a tumor suppressor mutated in half of colon cancers. Although p53 function appears important for proliferation arrest and apoptosis induced by cancer therapeutics, the prognostic significance of p53 mutations remains elusive. This suggests that p53 function is modulated at a posttranslational level and that dysfunctions affecting its modulators can have a prognostic impact. Among p53 modulators, homeodomain interacting protein kinase (HIPK) 2 emerges as a candidate “switch” governing p53 transition from a cytostatic to a proapoptotic function. Thus, we investigated the possible prognostic role of HIPK2 on a retrospective series of 80 colon cancer cases by setting up a multiplexed cytometric approach capable of exploring correlative protein expression at the single tumor cell level on TMA. Crossing the data with quantitative PCR and p53 gene sequencing and p53 functional assays, we observed the following: despite a strong impact on p21 transcription, the presence of disabling p53 mutations has no prognostic value, and the increased expression of the HIPK2 protein in tumor cells compared with paired normal tissue cells has a strong impact on survival. Unexpectedly, HIPK2 effect does not appear to be mediated by p53 function because it is also observed in p53-disabling mutated backgrounds. Thus, our results point to a prominent and p53-independent role of HIPK2 in colon cancer survival.

 

 Supported by the French National Institute for Medical Research (INSERM); Aquitaine Region, French Ministry of Research; Institut Bergonié; AMGEN France; ROCHE Laboratories; Association for Cancer Research; the Ligue Contre le Cancer; and Cancéropôle Grand Sud-Ouest and “Agir Cancer” Gironde.

 Supplemental material for this article can be found at http://ajp.amjpathol.org or at doi:10.1016/j.ajpath.2011.01.021.

PII: S0002-9440(11)00130-1

doi:10.1016/j.ajpath.2011.01.021

The American Journal of Pathology
Volume 178, Issue 5 , Pages 1986-1998, May 2011